Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Sanofi: Information concerning the total number of voting rights and shares - October 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II...
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria...
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive...
Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée La FDA a accepté l’examen de la sBLA pour le Dupixent dans le...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Sarclisa recommended for EU approval by the CHMP to treat...
Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe Sarclisa : approbation...
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination...
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Dupixent approved in the EU as the first and only medicine for young...
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.86 | -3.06341045416 | 93.36 | 94.4 | 90.17 | 1814274 | 91.84798315 | DE |
| 4 | -7.91 | -8.03780103648 | 98.41 | 101.9 | 90.17 | 1619800 | 95.67021175 | DE |
| 12 | -10.14 | -10.0755166932 | 100.64 | 106.14 | 90.17 | 1549285 | 100.17713939 | DE |
| 26 | 0.93 | 1.03829407168 | 89.57 | 106.14 | 85.94 | 1476531 | 96.02560974 | DE |
| 52 | 5.5 | 6.47058823529 | 85 | 106.14 | 83.28 | 1446217 | 92.79867252 | DE |
| 156 | 1.11 | 1.24174963642 | 89.39 | 106.66 | 76.45 | 1758300 | 92.46885427 | DE |
| 260 | 8.24 | 10.0170192074 | 82.26 | 106.66 | 67.65 | 1951544 | 89.31660651 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
103
